Antiviral therapy after curative treatment of hepatitis B/C virus‐related hepatocellular carcinoma: A systematic review of randomized trials
Authors:
- 2 April 2013
- journal article
- research article
- Published by Wiley in Hepatology Research
- Vol. 44 (3) , 259-269
Abstract
Aim Available published work on the benefit of adjuvant antiviral therapy after curative treatment of hepatocellular carcinoma (HCC) reports controversial results. The objective of this systematic review was to evaluate the effect of adjuvant antiviral therapy on recurrence and survival after curative treatment of HCC. Methods We conducted an extensive search strategy. All randomized controlled trials comparing adjuvant antiviral therapy versus placebo or no treatment were considered for this review. Results were expressed as hazard ratio for time‐to‐event outcomes with 95% confidence intervals using RevMan 5. Results We included nine trials (three of low risk of bias and six of unclear risk of bias) with 954 patients. All the included studies used conventional interferon (IFN) as adjuvant antiviral therapy; none of them used pegylated IFN or nucleoside analogs. There were significant improvements for recurrence‐free survival and overall survival in the adjuvant IFN group compared with the control group. Subgroup analysis also showed a significant difference favoring IFN therapy in hepatitis C virus (HCV)‐related HCC patients, but for hepatitis B virus (HBV)‐related patients, the difference failed to reach statistical significance. A dose reduction was needed in 28.3% of patients and discontinuation of IFN therapy happened in 8.2% of patients due to moderate to severe side‐effects. Conclusion Our study suggested potential benefits of adjuvant IFN therapy following curative treatment of HCC, especially for HCV‐related HCC. Further high‐quality randomized controlled trials of more effective adjuvant antiviral regimens, either used alone or in combination, for virus‐related HCC, especially HBV‐related HCC, are needed.Keywords
This publication has 40 references indexed in Scilit:
- Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trialsEuropean Journal of Surgical Oncology, 2012
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- A Randomized, Controlled Trial of Postoperative Adjuvant Interferon Therapy After Resection of Hepatocellular CarcinomaAnnals of Surgery, 2007
- Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosisHepatology, 2006
- Postoperative interferon α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trialJournal of Cancer Research and Clinical Oncology, 2006
- The global health burden of infection‐associated cancers in the year 2002International Journal of Cancer, 2006
- Evasion of intracellular host defence by hepatitis C virusNature, 2005
- Resection and Liver Transplantation for Hepatocellular CarcinomaSeminars in Liver Disease, 2005
- Updated treatment approach to hepatocellular carcinomaJournal of Gastroenterology, 2005
- 94 Prospective randomised trial on IFN-therapy for the secondary prevention of HCC recurrence after curative resection in HCV related cirrhosis. Preliminary reportJournal of Hepatology, 2004